Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H11O6.Cl |
Molecular Weight | 322.697 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].OC1=CC(O)=C2C=C(O)C(=[O+]C2=C1)C3=CC(O)=C(O)C=C3
InChI
InChIKey=COAWNPJQKJEHPG-UHFFFAOYSA-N
InChI=1S/C15H10O6.ClH/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7;/h1-6H,(H4-,16,17,18,19,20);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C15H10O6 |
Molecular Weight | 286.2363 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Cyanidin is a natural anthocyanidin present in fruits and vegetables, attenuates the development of several diseases, including asthma, diabetes, atherosclerosis, and cancer, through its anti-inflammatory effects. Its mechanism of action is still undefined, but it was revealed that cyanidin specifically recognizes an IL-17A binding site in the IL-17A receptor subunit (IL-17RA) and inhibits the IL-17A/IL-17RA interaction and thus can be used as a drug for the treatment of IL-17A-dependent inflammatory diseases and cancer. In addition, cyanidin was capable of inhibiting osteoclast formation and thus might have therapeutic potential for osteolytic diseases.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q96F46 Gene ID: 23765.0 Gene Symbol: IL17RA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28223414 |
3.0 µM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Cyanidin Stimulates Insulin Secretion and Pancreatic β-Cell Gene Expression through Activation of l-type Voltage-Dependent Ca(2+) Channels. | 2017 Jul 28 |
|
Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways. | 2018 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28223414
in mice: To examine the effect of A18 (also called cyanidin) on IL-17A–induced epidermal cell proliferation, it was intradermally injected the ears of female WT C57BL/6 mice with PBS or with IL-17A alone or together with A18 for six consecutive days. After the injections, the mice treated with IL-17 alone exhibited IL-17A–dependent epidermal hyperplasia, whereas the mice treated with both IL-17 and A18 exhibited reduced hyperplasia.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28788070
It was studied the mechanisms of cyanidin for stimulatory insulin secretion from pancreatic β-cells. Cyanidin (1–300 µM) stimulated insulin secretion and cyanidin (80 to 300 µM) increased intracellular Ca2+ signals in a concentration-dependent manner. The Ca2+ signals were abolished by nimodipine, an l-type voltage-dependent Ca2+ channel (VDCC) blocker or under extracellular Ca2+ free conditions. Stimulation of cells with cyanidin activated currents typical for VDCCs and up-regulated the expression of glucose transporter 2 (GLUT2), Kir6.2, and Cav1.2 genes.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:18:08 GMT 2023
by
admin
on
Sat Dec 16 04:18:08 GMT 2023
|
Record UNII |
2G4283G96U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1151924
Created by
admin on Sat Dec 16 04:18:08 GMT 2023 , Edited by admin on Sat Dec 16 04:18:08 GMT 2023
|
PRIMARY | |||
|
2G4283G96U
Created by
admin on Sat Dec 16 04:18:08 GMT 2023 , Edited by admin on Sat Dec 16 04:18:08 GMT 2023
|
PRIMARY | |||
|
CYANIDIN
Created by
admin on Sat Dec 16 04:18:08 GMT 2023 , Edited by admin on Sat Dec 16 04:18:08 GMT 2023
|
PRIMARY | |||
|
208-438-6
Created by
admin on Sat Dec 16 04:18:08 GMT 2023 , Edited by admin on Sat Dec 16 04:18:08 GMT 2023
|
PRIMARY | |||
|
528-58-5
Created by
admin on Sat Dec 16 04:18:08 GMT 2023 , Edited by admin on Sat Dec 16 04:18:08 GMT 2023
|
PRIMARY | |||
|
407291
Created by
admin on Sat Dec 16 04:18:08 GMT 2023 , Edited by admin on Sat Dec 16 04:18:08 GMT 2023
|
PRIMARY | |||
|
m3947
Created by
admin on Sat Dec 16 04:18:08 GMT 2023 , Edited by admin on Sat Dec 16 04:18:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
68247
Created by
admin on Sat Dec 16 04:18:08 GMT 2023 , Edited by admin on Sat Dec 16 04:18:08 GMT 2023
|
PRIMARY | |||
|
DTXSID80967263
Created by
admin on Sat Dec 16 04:18:08 GMT 2023 , Edited by admin on Sat Dec 16 04:18:08 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |